Stay updated with breaking news from வினய் கொனஜே. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Reuters Published: 07 Apr 2021 02:43 PM BdST Updated: 07 Apr 2021 02:43 PM BdST AstraZeneca vaccine against coronavirus disease (COVID-19) is seen in Laakso hospital in Helsinki, Finland Mar 11, 2021. REUTERS Indian drugmaker Shilpa Medicare Ltd has the capacity to manufacture 100-200 million doses of a protein-based vaccine for COVID-19, a company executive told Reuters on Wednesday. ); } India, the world s largest vaccine producing nation, has been ramping up the production of COVID-19 vaccines and global firms including AstraZeneca, US-based Novavax and Russia s RDIF have signed manufacturing deals with local players. RDIF, in particular, has already announced deals with six Indian companies to make more than half a billion doses of its Sputnik-V vaccine, including major drugmaker Dr Reddy s Laboratories and several smaller firms. ....
3 Min Read BENGALURU (Reuters) -Indian drugmaker Shilpa Medicare Ltd has the capacity to manufacture 100-200 million doses of a protein-based vaccine for COVID-19, a company executive told Reuters on Wednesday. Slideshow ( 2 images ) India, the world’s largest vaccine producing nation, has been ramping up the production of COVID-19 vaccines and global firms including AstraZeneca, U.S.-based Novavax and Russia’s RDIF have signed manufacturing deals with local players. RDIF, in particular, has already announced deals with six Indian companies to make more than half a billion doses of its Sputnik-V vaccine, including major drugmaker Dr Reddy’s Laboratories and several smaller firms. ....
India's Shilpa Medicare can make 100-200 mln doses of COVID-19 vaccine, says exec leaderpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from leaderpost.com Daily Mail and Mail on Sunday newspapers.